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Abstract
Background
Randomized controlled trials (RCT) have shown no overall benefit of renal revascularization
in atherosclerotic renovascular disease (ARVD). However, 25% of patients demonstrate
improvement in renal function. We used the ratio of magnetic resonance parenchymal vol-
ume (PV) to isotopic single kidney glomerular filtration rate (isoSKGFR) ratio as our method
to prospectively identify "improvers" before revascularization
Methods
Patients with renal artery stenosis who were due revascularization were recruited alongside
non-ARVD hypertensive CKD controls. Using the controls, 95% CI were calculated for
expected PV:isoSK-GFR at given renal volumes. For ARVD patients, “improvers” were
defined as having both >15% and >1ml/min increase in isoSK-GFR at 4 months after revas-
cularization. Sensitivity and specificity of PV:isoSK-GFR for predicting improvers was
calculated.
Results
30 patients (mean age 68 ±8 years), underwent revascularization, of whom 10 patients had
intervention for bilateral RAS. Stented kidneys which manifested >15% improvement in
function had larger PV:isoSK-GFR compared to controls (19±16 vs. 6±4ml/ml/min, p =
0.002). The sensitivity and specificity of this equation in predicting a positive renal functional
outcome were 64% and 88% respectively. Use of PV:isoSK-GFR increased prediction of
functional improvement (area under curve 0.93). Of note, non-RAS contralateral kidneys
which improved (n = 5) also demonstrated larger PV:isoSK-GFR (15.2±16.2 ml/ml/min, p =
0.006).
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Conclusion
This study offers early indicators that the ratio of PV:isoSK-GFR may help identify patients
with kidneys suitable for renal revascularization which could improve patient selection for a
procedure associated with risks. Calculation of the PV:isoSK-GFR ratio is easy, does not
require MRI contrast agent.
Introduction
Atherosclerotic renovascular disease (ARVD) is highly prevalent amongst patients with CKD
(up to 15% of CKD diagnoses [1]), and also those with atheromatous disease in other organ
systems (e.g. 47% of patients undergoing coronary artery bypass grafting have ARVD [2]). Sur-
vival is worse amongst ARVD patients than other causes of CKD [3]. Two large clinical trials
have shown no worthwhile benefit of renal artery revascularization as first line therapy over
medical therapy alone for renal artery stenosis (RAS) [4,5].
However, many of these patients had asymptomatic or incidental renovascular disease, and
others were excluded on the basis of an apparent pre-existing indication for intervention.
Questions therefore remain regarding the wider applicability of the results of ASTRAL and
CORAL to all patients with ARVD [6].
It is recognised that many individuals with RAS do benefit from stenting. Observational
studies demonstrate that 20–30% of patients show improvement in renal function after revas-
cularization [7,8]. In addition, 7% of ASTRAL patients randomized to revascularization expe-
rienced a complication from the procedure. What is not clear is how to predict which patients
will respond favourably. This would assist in reducing inappropriate and potentially harmful
interventions.
The diversity in renal functional outcome after revascularization is thought to reflect the
spectrum of the relative contributions of pre-existing parenchymal damage from long standing
hypertensive, atheromatous and cytokine insult, in addition to the simple hemodynamic
effects of the arterial narrowing, in the pathogenesis of the renal dysfunction [9, 10]. In most
patients, ARVD is a chronic process with a significant duration of hypertensive stress and
renal remodelling as a response to cytokine release [11]. Kidneys which demonstrate func-
tional improvement following revascularization may reflect a subgroup which have not under-
gone irreversible parenchymal structural damage. In a magnetic resonance imaging (MRI)
study by Cheung et al, we demonstrated the characteristics of a sub-group of kidneys that man-
ifest improved renal function post renal revascularization. These kidneys displayed a larger
MRI assessed parenchymal volume (PV) to radioisotope assessed single kidney glomerular
filtration (isoSK-GFR) [12]. The term ‘hibernating parenchyma’ can be used to describe this
subgroup of kidneys where renal dysfunction is thought to be potentially reversible with treat-
ment of the stenosis. This methodology was non–invasive and, although it used MRI, this did
not require administration of a gadolinium-based contrast agent. Also, this and most other
studies have not evaluated whether renal functional improvement after revascularization
translates into a survival benefit.
The aims of this study were: 1) to prospectively assess the validity and predictive power of
the PV:isoSK-GFR measurement; 2) to observe the longterm outcome in patients predicted to
improve after revascularization compared to those patients predicted to not improve. We also
studied the PV: isoSK-GFR relationship in non-RAS contralateral kidneys to determine
GFR:Renal volume predicts outcome in ARVD
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whether revascularization of a stenosed kidney can incidentally result in improvement in non-
RAS contralateral kidneys as a result of change in systemic neurohumoral responses [13].
Materials and methods
Patient recruitment
Ethics approval was granted by South Manchester Ethics Committee UK REC ref: 07/Q1405/
21 in accordance with the Declaration of Helsinki, and all patients gave written informed con-
sent prior to inclusion. Patients presenting to our tertiary referral centre between January 2007
and December 2010 who were due to undergo renal revascularization were approached to
participate in this study. The clinical decision to consider revascularization was based on: 1)
clinical grounds (e.g. poorly controlled hypertension on 4 or more anti-hypertensive agents,
deteriorating renal function, or flash pulmonary oedema) or 2) randomization into the revas-
cularization arm of an ongoing clinical trial, either the ASTRAL (ISRCTN59586944) [4] or
CORAL[5] (NCT0008173) trials.
Control patients were those attending the renal clinic in whom there had been clinical sus-
picion of ARVD (i.e. signs and symptoms suggestive of renovascular disease such as poorly
controlled hypertension, CKD, arterial bruits or discrepant kidney sizes), but who had no evi-
dence of RAS detectable by MR or CT angiography. The purpose of this control group was to
assess renal PV:isoSK-GFR changes in hypertensive patients without RAS (rather than in
healthy controls) in order to devise an appropriate reference group for comparison of PV:
isoSK-GFR.
Sample size calculation
From our pilot study [12], kidneys that showed a difference between actual and predicted PV:
isoSK−GFR of>2ml/ml/min were more likely to show improved renal function after revascu-
larization compared to those with PV:isoSK−GFR differing by <2ml/ml/min. Using the SD,
which was 1.5ml/ml/min, the number of kidneys (that manifest improved function) required
to detect a difference of 2ml/ml/min between actual and predicted PV:isoSK−GFR with a sig-
nificance level of 0.05 and 90% power was 15. In the pilot study, 7 of the 16 revascularized kid-
neys (44%) showed improved function. Hence, it was estimated that 35 kidneys would need to
be revascularized within this study.
Radioisotope single-kidney GFR (isoSK-GFR)
All patients underwent baseline assessment of individual kidney function involving a standard
radioisotopic methodology [14–16]. Overall GFR was first measured with 51Cr-Ethylenedi-
aminetetraacetic acid (51Cr-EDTA) clearance. 99mTc-dimercaptosuccinic acid (99mTc-DMSA)
scintigraphy was then used to assess the differential static radioisotope uptake of each kidney.
The isoSK-GFR was expressed as an absolute individual value in ml/min and not ml/min/
1.73m2 as body surface area was calculated for each patient. In patients who underwent renal
revascularization, isoSK-GFR was also repeated at 4 months following the procedure. The
daily variation in isoSK-GFR has been shown to be 8.8% [14]. The criteria for clinically rele-
vant change in individual renal function were >15% and>1ml/min increase of isoSK-GFR at
4 months post-revascularization compared to baseline. This was to account for small, low GFR
kidneys which may experience a large percentage increase which does not translate to a large
absolute increase in ml/min. Following revascularization, both the revascularizaed and contra-
lateral kidneys were classified as having improved, remained stable or deteriorated based upon
the following thresholds: improved = isoSK-GFR increased by at least 1ml/min and by >15%
GFR:Renal volume predicts outcome in ARVD
PLOS ONE | https://doi.org/10.1371/journal.pone.0177178 June 8, 2017 3 / 14
compared to baseline; deteriorated = isoSK-GFR decreased by at least 1ml/min and by >15%
compared to baseline; stable = changes between the above 2 definitions.
Magnetic resonance imaging
Data were collected using a 3 T whole-body MR scanner (Philips Acheiva, Philips Medical Sys-
tems Lts, NL). Following acquisition of scout images a 3D imaging volume was acquired using
a T1-weighted spoiled gradient echo acquisition in the oblique-coronal plane. The volume
encompassed both kidneys and the descending aorta and the data were obtained in a single
breathhold. Gadolinium was not used for acquisition of the data. The following parameters
were used for the acquistion: TR = 4.0ms, TE = 1.0ms, FOV = 400x400x80mm, flip angle = 14
degrees, 2 signal averages, parallel acquisition using a SENSE factor = 2, following interpola-
tion in the Fourier domain matrix = 256x256x40). The parenchymal volumes were calculated
from the 3D volume images using the voxel-count method as we have previously described
[12,17].
Renal volume ðmlÞ ¼
X
ðparenchymal area x slice thicknessÞn’th slice
Analysis of PV: isoSK-GFR
With renal damage and shrinkage, loss of cortical tissue occurs to a greater degree than that
of the medulla [18] and hence the ratio of PV to isoSK-GFR would increase as the kidney
decreases in size. Control kidneys were grouped into 5 categories according to their parenchy-
mal volume and these groups used to define reference ranges for PV:isoSK-GFR ratio at a
given volume. Kidneys were considered to have a high PV:isoSK-GFR ratio, and therefore be
predicted to respond to revascularisation, when this exceeded the upper limit of the 95% CI
for a control kidney of a given volume group. These criteria were set pre-emptively, before the
study began.
Evaluation criteria and statistical analysis
Parametric data are presented as mean±standard deviation and non-parametric data as
median (interquartile range). Differences in baseline continuous variables between groups
were assessed using ANOVA with natural log transformation applied to non-normal varaibles;
baseline categorical variables were compared using chi-square test.
To account for possible effects of regression to the mean due to the non-randomized
design, between group comparison of MRI parameters of kidneys with stable, improving or
deterirorating function post-revascularization was performed using analysis of covariance
(ANCOVA) incorporating follow-up isoSK-GFR data in a least squared means model.
Homogeneity of slopes was assessed by including a class-by-covariate interaction term and
ANCOVA plots (negative in all cases). Standard error results were calculated to compare the
study population mean versus the mean of the true population.
As follow up isoSK-GFR data were not obtained for control kidneys, comparison between
these and revascularized kidneys was made using standard ANOVA methodology. Sensitivity /
specificity analysis was performed using receiver operating characteristic (ROC) curves and
integrated discrimination improvement analysis with isoSK-GFR data considered in addition
to baseline renal functional parameters.
A survival analysis was performed to compare outcome in improvers versus non-improv-
ers. Because some patients underwent bilateral revascularization, for this analysis responders
GFR:Renal volume predicts outcome in ARVD
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were defined as those patients with improvement in isoSK-GFR >15% of any revascularized
kidney. Outcome was all-cause mortality and follow up was until death or 31st December 2015.
A Cox proportional hazard model was used, adjusted for age and overall GFR at baseline. The
study was not powered specifically for this survival analysis.
In all cases statistical significance was defined as an alpha value of<0.05. Analyses were
performed in SAS version 9.2 (SAS Institute, Cary, NC, USA) under licence to the University
of Manchester with figures generated in R version 3.0.1.
Results
During the study period, 275 patients were screened for ARVD. These patients had a mean age
of 68±10 years. Patient recruitment is summarised in Fig 1, including the individual reasons
for non-inclusion. There were 30 ARVD patients who underwent revascularization that were
included in the final analysis, and 14 non-ARVD hypertensive CKD controls.
The baseline phenotype of the study subjects is shown in Table 1. Revascularized patients
were significantly older than non-ARVD controls, had a lower GFR, and were more likely to
have smoked. Of the 30 patients who were revascularized, 20 had unilateral and 10 bilateral
revascularization. This gave a total of 40 revascularized kidneys for analysis, and 20 contralat-
eral non-RAS kidneys.
Indications for revascularization were: randomized to revascularization within the ASTRAL
and CORAL trials (n = 7), severe hypertension (n = 8), rapidly deteriorating renal function
(n = 9), flash pulmonary oedema (n = 2), poorly controlled heart failure and chest pain (n = 1),
to preserve renal mass or prevent renal artery occlusion (RAO) during planned cardiac bypass
(n = 2), to enable use of renin angiotensin blockade (RAB) for treatment of hypertension and
proteinuria (n = 1).
Renal functional response in individual kidneys
There was no significant difference in baseline renal function between stented kidneys and
contralateral kidneys, although contralateral kidneys which remained stable tended to have
better baseline isoSK-GFR and larger volumes. Stented kidneys which improved had a mean
Fig 1. Summary of recruitment flow.
https://doi.org/10.1371/journal.pone.0177178.g001
GFR:Renal volume predicts outcome in ARVD
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PV:isoSK-GFR ratio 2.8 times larger than those which remained stable or deteriorated, and 3.1
times greater than controls. The PV:isoSK-GFR ratio of stented kidneys which improved was
noted to decrease significantly post revascularization (Fig 2).
Contralateral kidneys that improved had PV:isoSK-GFR ratios 1.7 and 1.5 times greater
than contralateral kidneys which remained stable or deteriorated respectively, and 2.4 times
greater than control kidneys.
The mean change in overall radioisotope GFR from pre-stent baseline to 4 months post-
procedure for the 30 patients who underwent revascularization was 1.3±12.4 mL/min. For the
40 stented kidneys, the mean change in isoSK-GFR was 1.2±10.2 mL/min and for the 20 non-
RAS contralateral kidneys the mean change was 0.5±2.1 mL/min. Differences in MRI and
radioisotope measurements between patients with improving / stable / deteriorating
isoSK-GFR after revascularization are shown in Table 2.
There was no significant correlation between severity of RAS and isoSK-GFR (r = 0.094,
p = 0.384), PV (r = 0.094, p = 0.384) or PV:isoSK-GFR (r = 0.008, p = 0.942). Male patient
Table 1. Baseline demographics of control and revascularized subjects.
Treatment group Control group p
Mean (SD) Range Mean (SD) Range
N 30 14 -
Age (years) 68.9 (8.9) 51–82 59.4 (12) 39–81 0.005
Male (n, %) 19 (63.3%) 7 (50%) 0.402
Weight (kg) 75.7 (14.4) 55–110 85 (20.8) 44–115 0.089
Height (cm) 164.2 (8.5) 143–178 166.6 (12.2) 150–185 0.46
BMI (kg/m2) 28 (4.4) 21–38 31.5 (7.7) 15–47 0.062
SBP (mmHg) 158.4 (30.9) 103–214 148.6 (32.5) 107–220 0.339
DBP (mmHg) 79.8 (17.9) 37–109 83.1 (12.3) 56–109 0.545
N anti-hypertensives 3.7 (2.2) 0–10 2.8 (2) 0–7 0.176
Biochemical parameters
eGFR (ml/min/1.73m2) 41.4 (22.6) 12–90 59.8 (19.6) 32–90 0.012
Isotopic GFR (ml/min) 35.1 (18.9) 7–72 56.2 (25) 25–112 0.003
Haemoglobin (g/l) 123.2 (16.9) 84–164 131.6 (16.9) 105–154 0.145
uPCR (g/mol) 63 (121) 0–568 40 (60) 0–158 0.991
Serum albumin (g/l) 45.8 (7.3) 40–80 45.1 (2.7) 41–48 0.737
Cholesterol (mmol/l) 4.2 (0.9) 3–6 4.4 (0.8) 3–6 0.478
Comorbid conditions
Hypertension 29 (96.7%) 13 (92.9%) 0.572
Previous MI 12 (40%) 2 (14.3%) 0.088
PVD 7 (23.3%) 2 (14.3%) 0.488
Type II diabetes 11 (36.7%) 4 (28.6%) 0.598
Current smoker 5 (16.7%) 3 (21.4%) 0.703
Ex-smoker 13 (43.3%) 1 (7.1%) 0.016
Prescribed medications
RAAS blockade 22 (73.3%) 7 (50%) 0.128
Aspirin 20 (66.7%) 7 (50%) 0.290
Statin 23 (76.7%) 11 (78.6%) 0.888
Estimated GFR calculated using 4-variable MRDR equation. Angiotensin blockade defined as prescription of angiotensin converting enzyme inhibitor,
angiotensin II receptor blocker, or direct renin inhibitor.
https://doi.org/10.1371/journal.pone.0177178.t001
GFR:Renal volume predicts outcome in ARVD
PLOS ONE | https://doi.org/10.1371/journal.pone.0177178 June 8, 2017 6 / 14
Fig 2. Box plot showing baseline (grey) and follow up (white) PV:isoSK-GFR characteristics in improver, stable and
deteriorator kidneys. *P<0.05 within group.
https://doi.org/10.1371/journal.pone.0177178.g002
Table 2. Comparison of imaging measurements between groups divided by renal functional outcome, comparing these outcome groups for
stented ARVD kidneys and non-ARVD contralateral kidneys. Between group statistical analysis is by ANCOVA.
Outcome Stented kidneys (n = 40) Contralateral kidneys (n = 20)
SK-GFR (mL/min) PV (mL) Ratio (min-1) SK-GFR (mL/min) PV (mL) Ratio (min-1)
Improved >15% 11.0 (2.2) 113.4 (3.9) 19.4 (16.2) 13.7 (0.9) 102.4 (6.2) 15.2 (6.2)
Stable 20.6 (1.6) 124.4 (2.9) 7.0 (3.3) 14.9 (0.6) 106.3 (3.8) 8.7 (6.7)
Deteriorated >15% 25.1 (2.6) 121.9 (4.5) 7.1 (5.0) 16.8 (1) 110.2 (5.7) 10.0 (5.2)
P <0.001 0.01 <0.001 0.09 0.6 0.23
Results are presented as mean (standard error). GFR = isotope glomerular filtration rate, PV = parenchymal volume, SK = single kidney, Ratio = PV divided
by GFR.
https://doi.org/10.1371/journal.pone.0177178.t002
GFR:Renal volume predicts outcome in ARVD
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improver kidneys had larger volumes than female kidneys. However, there was no significant
between sex difference in the PV:isoSK-GFR ratio.
Control kidneys as the reference group
Control kidneys were grouped into 5 reference categories according to their baseline volumes
(ml) and isoSK-GFR. The PV:isoSK-GFR ratios were calculated for each volume group
(Table 3). The ratio of PV:isoSK-GFR increased as the renal volume increased. In the smallest
volume group (<85mL), the mean PV:isoSK-GFR was 4.5 (0.5–9.5). By comparison, in the
largest volume group (>170mL), the mean PV:isoSK-GFR was 10.8 (0.1–21.7). Analysis using
these reference groups showed that both stented and contralateral kidneys with baseline PV:
isoSK-GFR that exceeded the 95% CI for a given volume of a control kidney were more likely
to show renal functional improvement post revascularization (Fig 3).
Sensitivity and specificity
The area under the ROC curve (AUC) for baseline isoSK-GFR in predicting a >15% increase
in isoSK-GFR following revascularization was 0.81. When PV:isoSK-GFR was added this
increased to 0.93 with an integrated discrimination improvement of 0.27, p = 0.001 (Fig 4).
The sensitivity and specificity of PV:isoSK-GFR ratio in predicting beneficial functional
outcomes for stented kidneys were 64% and 88%, respectively (Table 4). The ratio was more
sensitive but less specific in contralateral kidneys (80% and 67%, respectively). The positive
predictive value of the PV:isoSK-GFR ratio for improver response was 75% in stented and 80%
in contralateral kidneys. The negative predictive value was 82% in stented and 67% in contra-
lateral kidneys. The area under the curve was 0.938, p<0.0001 for combined stented and con-
tralateral kidneys.
Survival analysis
Over a mean 6.1±2.6 years follow up after revascularization, there were 12 deaths in the treat-
ment group (40%); 5 patients progressed to end stage kidney disease necessitating dialysis
(28%), of whom 2 died. The estimate of mean survival time for improvers was 6.7 year (95%
CI 5.3–8.2 years) compared with 5.7 (4.3–7.1) years in non-improvers, and 7.4 (6.3–8.5) years
in the control group. In a Cox proportional hazard model adjusted for baseline age, GFR,
gender, diabetes, blood pressure, and coronary artery disease the hazard ratio for death in
improvers versus non-improvers was 0.51 (0.16–1.61), p = 0.251. Survival curves comparing
improvers with non-improvers and showing control patients is found in Fig 5. There were no
statistically significant differences in baseline characteristics between improvers and non-
improvers (a full comparison of characteristics is found in online Table 1).
Table 3. PV:isoSK-GFR characteristics of control kidneys used to establish 95% CI.
Volume group (ml) N PV:isoSK-GFR
(mean (95% CI) min-1)
<85.0 3 4.5 (0.5–9.5)
85 to 110 4 5.0 (3.6–8.4)
110.01 to 140 6 5.4 (2.7–8.1)
140.01 to 170 10 5.9 (4.6–7.3)
>170 5 10.8 (0.1–21.7)
https://doi.org/10.1371/journal.pone.0177178.t003
GFR:Renal volume predicts outcome in ARVD
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The Cox proportional hazard model was repeated to compare those predicted to respond
versus those predicted to not respond, based on isoSK:GFR. Here, the adjusted hazard ratio for
death in predicted improvers versus predicted non-improvers was 0.54 (0.15–1.95), p = 0.354.
To observe the potential effect of differences in blood pressure control after revasculariza-
tion on outcome in improvers versus non-improvers, we compared baseline blood pressure
and change in blood pressure at one month after revascularization between the two groups.
The mean baseline systolic blood pressure in improvers was 159±25 mmHg compared with
Fig 3. Percentage change in isoSK-GFR at 4 months post-revascularization grouped according to PV:isoSK-GFR
ratio. “High ratio” indicates those kidneys which had a PV:isoSK-GFR that exceeded the 95% CI for a given volume of a
control kidney.
https://doi.org/10.1371/journal.pone.0177178.g003
GFR:Renal volume predicts outcome in ARVD
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158±33 mmHg in non-improvers (unpaired t-test p = 0.774); baseline diastolic blood pressures
were 87±17 mmHg and 78±17 mmHg, respectively (p = 0.143). The mean changes in systolic
blood pressure were -19±42mmHg in improvers and -17±63mmHg (p = 0.463) in non-
improvers, and change in diastolic blood pressure was -6±18mmHg and -8±32mmHg respec-
tively, (p = 0.865).
Discussion
The most important finding of this study was that a higher PV:isoSK-GFR ratio pre-revascu-
larization is noted in patients whose renal function improves after revascularization. Stented
kidneys which improved had a ratio 3 times higher than those which deteriorated or remained
stable. The higher the PV:isoSK-GFR, the more specific the ratio was in determining outcome,
Fig 4. Receiver operating characteristic curves for >15% improvement in isoSK-GFR following
revascularization. Dashed line represents isoSK-GFR (AUC 0.81). Solid line represents addition of PV:
isoSK-GFR values (AUC 0.93).
https://doi.org/10.1371/journal.pone.0177178.g004
Table 4. Comparison of predicted versus actual outcomes for individual stented kidneys.
Actual response
Predicted response Improver (% of predicted) Non-improver (% of predicted)
Improver 9 (64) 5 (36)
Non-improver 3 (12) 23 (88)
https://doi.org/10.1371/journal.pone.0177178.t004
GFR:Renal volume predicts outcome in ARVD
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although the sensitivity remained moderate (Sig 1). Using ROC analysis, RAS kidneys
improved 94% of the time if PV:isoSK-GFR is>95% CI of the control group. In this study,
27% of kidneys improved, which is comparable to other studies that have reported on renal
functional response. This emphasizes the need for suitable pre-selection criteria [19].
Importantly, improvement was seen even in kidneys with small SK-GFR (6 revascularized
kidneys had baseline isoSK-GFR <10ml/min). These kidneys would not usually have been
considered suitable for revascularization by most clinicians. However, a previous twin centre
study has shown that the most significant improvements in renal function may actually
accompany revascularization of ARVD patients with advanced CKD [7], and the current study
suggests that patients could be delayed from progressing to dialysis should the PV:isoSK-GFR
ratio of these low function kidneys be suitably large.
Another finding of this study is that some non-ARVD, non-revascularized kidneys contra-
lateral to the revascularized kidney also experienced an improvement in renal function if they
had a larger baseline PV:isoSK-GFR. This was more likely in but not exclusive to cases where
the stented kidney improved.
We presume that this improvement in contralateral kidneys relates to neurohumoral
changes (e.g. changes in renin, and angiotensin) or sympathetic nerve activity, or changes in
blood pressure control. Thus even kidneys not directly affected by RAS may have the potential
for improvement, and the implication is that the PV:SK-GFR may serve as a surrogate of renal
functional reserve in either kidney.
The improver contralateral kidneys with larger PV: isoSK-GFR did not demonstrate a sig-
nificant drop in this ratio post revascularization, unlike the stented kidneys which did. Both
volume and isoSK-GFR improvements occurred in the contralateral kidneys, whereas the
isoSK-GFR improvement seemed to exceed that of volume expansion in the stented kidney.
Fig 5. Survival curves for revascularized patients divided into improvers versus non-improvers, and
comparing with non ARVD control patients, adjusted for baseline age, co-morbidities, and GFR.
https://doi.org/10.1371/journal.pone.0177178.g005
GFR:Renal volume predicts outcome in ARVD
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One hypothesis to explain these differences could be that ‘hibernating parenchyma’ was pres-
ent within the improver stented kidneys, with return of blood flow to the ischaemic tissue lead-
ing to proportionately greater improvement of GFR rather than volume, given that irreversible
structural change had not occurred. In our previous pilot study [12], we found that patients
who had high PV:isoSK-GFR kidneys with significant RAS who were treated conservatively
were 7 times more likely to show significant decline of eGFR at 1 year compared to their revas-
cularized counterparts. Conversely, with revascularized patients, treatment of a significant
RAS kidney that had a high PV:SK-GFR ratio was 28 times more likely to show GFR improve-
ment compared to conservatively managed patients. A large PV:isoSK-GFR is thought to rep-
resent the fact that ‘hibernating’ renal tissue is present which is not irreversibly damaged and
which is still salveagable with revascularization.
The survival analysis showed a numerical but not statistical survival benefit for improvers
over non-improvers. In fact, that outcome for improvers more closely matched that of the con-
trol patients than the non-improvers. This must be taken in the context of the fact that this
study was not powered to a survival analysis. Nonetheless, such a trend towards improved sur-
vival in the improver group supports the hypothesis that not only can PV:isoSK-GFR predict
the likelihood of a renal functional response to revascularization but that such a response is a
surrogate for improved prognosis for ARVD patients. Given the neutral results of ASTRAL
and CORAL indicating that revascularization should not be seen as first line therapy for the
majority of patients with ARVD, a simple technique such as that described here may enhance
the required screening to select those patients who should be revascularized.
The key limitation of this study is the small patient numbers. This was a pilot study and not
designed to provide conclusive answers. Nonetheless, it does inform us that this is an area of
potential clinically utility in the future. A second limitation of this study is the two-stop nature
of the diagnostic tool. A one-stop approach would benefit patients and likely be more cost-
effective in day to day practice. We have previously described the use of BOLD MRI signal in
predicting renal functional response to revascularization with similar sensitivity and specificity
to the volume based approached described here [20]. The use of MRI to accurately measure
SK-GFR is emerging [21]. Alternatively, and for patients who are unable to undergo MRI (e.g.
those with heart failure and device in situ), CT-measured volume and GFR may provide an
alternative approach.
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